z-logo
open-access-imgOpen Access
Treatment of Delusions in Alzheimer’s Disease – Response to Pharmacotherapy
Author(s) -
Corinne E. Fischer,
Radenka Bozanovic,
Jana H. Atkins,
Sean B. Rourke
Publication year - 2006
Publication title -
dementia and geriatric cognitive disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.026
H-Index - 110
eISSN - 1421-9824
pISSN - 1420-8008
DOI - 10.1159/000094975
Subject(s) - donepezil , dementia , risperidone , antipsychotic , olanzapine , disease , psychiatry , psychosis , alzheimer's disease , parkinsonism , extrapyramidal symptoms , medicine , galantamine , rivastigmine , randomized controlled trial , psychology , pharmacotherapy , schizophrenia (object oriented programming)
Delusions are commonly encountered symptoms in patients with Alzheimer's disease and may lead to significant morbidity. The purpose of this article is to review all clinical trials to date focusing on the management of delusions in patients with Alzheimer's disease to determine the level of evidence for treatment. To achieve this objective, Medline was searched using the key words delusions, dementia, Alzheimer's disease and psychosis. Three main categories of treatment were identified: atypical antipsychotics, cholinesterase inhibitors, and other miscellaneous treatments. It was concluded that all forms of treatment were effective although the greatest burden of evidence existed for risperidone and donepezil. Side effects were noted in all forms of treatment and included somnolence and extrapyramidal effects for antipsychotic medications, whereas gastrointestinal effects were more prevalent in studies involving cholinesterase inhibitors. Further large scale, double-blind, randomized, controlled studies are required before a definitive conclusion can be reached. To our knowledge this is the only systematic review of this area.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom